Your browser doesn't support javascript.
loading
Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Araki, Eiichi; Mathieu, Chantal; Shiraiwa, Toshihiko; Maeda, Hajime; Ikeda, Hiroki; Thoren, Fredrik; Arya, Niki; Asano, Michiko; Iqbal, Nayyar.
  • Araki E; Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Mathieu C; Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium.
  • Shiraiwa T; Shiraiwa Medical Clinic, Osaka, Japan.
  • Maeda H; H.E.C. Science Clinic, Yokohama, Japan.
  • Ikeda H; Ikeda Hospital, Amagasaki, Japan.
  • Thoren F; Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Arya N; Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Asano M; Research & Development, AstraZeneca K.K., Osaka, Japan.
  • Iqbal N; Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Diabetes Obes Metab ; 23(7): 1496-1504, 2021 07.
Article en En | MEDLINE | ID: mdl-33620762
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 Tipo de estudio: Clinical_trials Límite: Humans País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 Tipo de estudio: Clinical_trials Límite: Humans País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article